CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
CTLA4启动子甲基化可预测接受抗CTLA-4免疫疗法（伊匹木单抗）治疗的IV期黑色素瘤患者的疗效和无进展生存期
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-020-02777-4
Fietz, Simon; Zarbl, Romina; Niebel, Dennis; Posch, Christian; Brossart, Peter; Gielen, Gerrit H; Strieth, Sebastian; Pietsch, Torsten; Kristiansen, Glen; Bootz, Friedrich; Landsberg, Jennifer; Dietrich, Dimo
